Antivascular ultrasound therapy extends survival of mice with implanted melanomas

Ultrasound in Medicine and Biology

Volumn 36, Issue 5, 2010, Pages 853-857

  Wood, Andrew K W ^a   Schultz, Susan M ^b   Lee, William M F ^b   Bunte, Ralph M ^a   Sehgal, Chandra M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Antivascular; Low intensity ultrasound therapy; Melanoma; Ultrasound contrast agent

Indexed keywords

ANGIOGENESIS; ANTIVASCULAR; CONTROL GROUPS; DEFINITY; INTRAVENOUS INJECTIONS; LOW INTENSITY ULTRASOUND; LOW-INTENSITY; MEDIAN SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TIME CURVES; ULTRASOUND CONTRAST AGENT; ULTRASOUND THERAPY; ULTRASOUND TREATMENTS;

ACOUSTIC FIELDS; DERMATOLOGY; ONCOLOGY; TUMORS; ULTRASONIC TRANSMISSION;

ULTRASONICS;

PERFLUTREN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVASCULAR ULTRASOUND THERAPY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; GROWTH RATE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PLOTS AND CURVES; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME; ULTRASOUND THERAPY;

ANIMALS; CELL LINE, TUMOR; MELANOMA; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; ULTRASONIC THERAPY;

EID: 77952320392     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2010.02.001     Document Type: Article

References (24)

1. Baguley B.C. Antivascualr therapy of cancer: DMXAA. Lancet Oncol 2003, 4:141-148.
2. Beerepoot L.V., Radema S.A., Witteveen E.O., Thomas T., Wheeler C., Kempin S., Voest E.E. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006, 24:1491-1498.
3. Briones J.R., Serra A.C., Lozano A.G., Ramón-Borja J.C., Juan I.I., Narbón E.S. High-intensity focused ultrasound in small renal masses. Adv Urol 2008, article ID 809845; Epub December 31, 2008.
4. Bunte R.M., Ansaloni S., Sehgal C.M., Lee W.M.-F., Wood A.K.W. Histpathological observations of the antivascular effects of physiotherapy ultrasound on a murine neoplasm. Ultrasound Med Biol 2006, 32:453-461.
5. Chabot G.G., Bissery M.C., Corbett T.H., Rutkowski K., Baker L.H. Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. Cancer Chemother Pharmacol 1989, 24:15-22.
6. Chaplin D.J., Hill S.A. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 2002, 54:1491-1496.
7. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumor therapy. Br J Cancer 1982, 45:136-139.
8. Denekamp J., Hill S.A., Hobson B. Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 1983, 19:271-275.
9. Folkman J. Angiogenesis. Harrison's textbook of internal medicine 2001, 517-530. McGraw-Hill, New York. E. Braunwald, A.S. Fauci, D.L. Kasper, D.L. Longo, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds.).
10. Hande K.R., Hagey A., Berlin J., Cai Y., Meek K., Kobayashi H., Lockhart A.C., Medina D., Sosman J., Gordon G.B., Rothenberg M.L. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006, 12:2834-2840.
11. Hinnen P., Eskens F.A. Vascular disrupting agents in clinical development. Br J Cancer 2007, 96:1159-1165.
12. Lippert J.W. Vascular disrupting agents. Bioorg Med Chem 2007, 15:605-615.
13. Maestroni U., Ziveri M., Azzolini N., Dinale F., Ziglioli F., Campaniello G., Frattini A., Ferretti S. High intensity focused ultrasound (HIFU): A useful alternative choice in prostate cancer treatment. Preliminary results. Acta Biomed 2008, 79:211-216.
14. Nielsen T., Murata R., Maxwell R.J., Stødkilde-Jørgensen H., Ostergaard L., Horsman M.R. Preclinical studies to predict efficacy of vascular changes induced by combretastatin A-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys 2008, 70:859-866.
15. Rustin G.J., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., Gumbrell L., Price P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 2003, 21:2815-2822.
16. Rustin G.J., Bradley C., Galbraith S., Stratford M., Loadman P., Waller S., Bellenger K., Gumbrell L., Folkes L., Halbert G. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer 2003, 88:1160-1167.
17. Salmon B.A., Siemann D.W. Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 2007, 68:211-217.
18. Sehgal C.M., Cary T.W., Arger P.H., Wood A.K.W. Delta projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion. Acad Radiol 2009, 16:71-78.
19. Susani M., Madersbacher S., Kratzik C., Vingers L., Marberger M. Morphology of tissue destruction induced by focused ultrasound. Eur Urol 1993, 23(Suppl 1):34-38.
20. Tozer G.M., Kanthou C., Lewis G., Prise V.E., Vojnovic B., Hill S.A. Tumour vascular disrupting agents: Combating treatment resistance. Br J Radiol 2008, 81(Spec No 1):S12-S20.
21. Van Leenders G.J.L.H., Beerlage H.P., Ruijter E.T., de la Rosette J.J., van de Kaa C.A. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localized adenocarcinoma of the prostate. J Clin Pathol 2000, 53:391-394.
22. Wood A.K.W., Ansaloni S., Ziemer L.S., Lee W.M.-F., Feldman M.D., Sehgal C.M. The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol 2005, 31:1403-1410.
23. Wood A.K.W., Bunte R.M., Cohen J., Tsai J.H., Lee W.M.-F., Sehgal C.M. The antivascular action of physiotherapy ultrasound on a murine tumor: Role of a microbubble contrast agent. Ultrasound Med Biol 2007, 33:1901-1910.
24. Wood A.K.W., Bunte R.M., Price H., Deitz M., Tsai J.H., Lee W.M.-F., Sehgal C.M. The disruption of murine tumor neovasculature by low-intensity ultrasound-comparison between 1 MHz and 3 MHz sonication frequencies. Acad Radiol 2008, 15:1133-1141.